P0745 Effectiveness of Switching to Subcutaneous Infliximab in Inflammatory Bowel Disease Patients with Inadequate Biochemical Response during Intravenous Administration
Authors: Kim M , Lee B , Kim E R , Hong S N , Chang D K , Kim Y H 
Published: January 2025

Background

Infliximab (IFX) has transformed the management of inflammatory bowel diseases (IBD). While intravenous (IV) IFX has been effective, a subcutaneous (SC) formulation offers advantages in convenience and cost. However, there is lack of evidence regarding the transition from IV to SC-IFX, especially for patients with inadequate responses. This study investigates the effectiveness of switching from IV to SC-IFX in patients with inadequate biochemical response during IV maintenance therapy.

Methods

A retrospective study enrolled IBD patients who transitioned to SC-IFX after demonstrating inadequate biochemical response during IV maintenance therapy. The study collected data of demographics of patients and dose and therapies administered prior to the IV-IFX. Primary outcomes included improvements in C-reactive protein (CRP) or fecal calprotectin (FC) levels. This study evaluated the trough levels and its differences between pre- and post-switching.

Results

Among 44 patients included, 10 exhibited CRP elevation before the switch, with 6 showing normalization post-switch. Similarly, 42 patients had elevated FC levels pre-switch, with 26 experiencing reductions post-switch. Trough levels increased after the switch. However, there were no significant differences in trough levels between responders and non-responders.

Conclusion

This study aims to investigate the transition therapy of IV to SC-IFX in patients with inadequate biochemical response. This suggests that SC-IFX could be a viable alternative in the management of IBD. However, further research is necessary to evaluate its efficacy in a larger population of patients who exhibit inadequate responses during IV-IFX maintenance therapy.

References

et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 362, 1383-1395. http://doi.org/10.1056/NEJMoa0904492 (2010). et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut 58, 501-508. http://doi.org/10.1136/gut.2008.163642 (2009). et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359, 1541-1549. http://doi.org/10.1016/s0140-6736(02)08512-4 (2002).J Clin Gastroenterol 49, 582-588. http://doi.org/10.1097/mcg.0000000000000319 (2015). et al. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet 380, 1909-1915. http://doi.org/10.1016/s0140-6736(12)61084-8 (2012). et al. Long-term outcome of patients with steroid-refractory acute severe UC treated with ciclosporin or infliximab. Gut 67, 237-243. http://doi.org/10.1136/gutjnl-2016-313060 (2018). et al. Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial. Gastroenterology 130, 1054-1061. http://doi.org/10.1053/j.gastro.2006.02.014 (2006). et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 340, 1398-1405. http://doi.org/10.1056/nejm199905063401804 (1999). et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 353, 2462-2476. http://doi.org/10.1056/NEJMoa050516 (2005). et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 350, 876-885. http://doi.org/10.1056/NEJMoa030815 (2004). et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut 58, 492-500. http://doi.org/10.1136/gut.2008.155812 (2009). et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 337, 1029-1035. http://doi.org/10.1056/nejm199710093371502 (1997).Clin Drug Investig 42, 477-489. http://doi.org/10.1007/s40261-022-01162-6 (2022). et al. Innovative approaches to biologic development on the trail of CT-P13: biosimilars, value-added medicines, and biobetters. MAbs 13, 1868078. http://doi.org/10.1080/19420862.2020.1868078 (2021). et al. Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era. Adv Ther 39, 2342-2364. http://doi.org/10.1007/s12325-021-01990-6 (2022). et al. Randomized Controlled Trial: Subcutaneous vs Intravenous Infliximab CT-P13 Maintenance in Inflammatory Bowel Disease. Gastroenterology 160, 2340-2353. http://doi.org/10.1053/j.gastro.2021.02.068 (2021). et al. Subcutaneous Infliximab in Refractory Crohn's Disease Patients: A Possible Biobetter? Crohns Colitis 360 5, otad040. http://doi.org/10.1093/crocol/otad040 (2023).Medicine (Baltimore) 101, e30683. http://doi.org/10.1097/md.0000000000030683 (2022). et al. STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. Gastroenterology 160, 1570-1583. http://doi.org/10.1053/j.gastro.2020.12.031 (2021).Gastroenterology 154, S-1371 (2018). et al. Introduction of Subcutaneous Infliximab CT-P13 and Vedolizumab in Clinical Practice: A Multi-Stakeholder Position Statement Highlighting the Need for Post-Marketing Studies. J Crohns Colitis 16, 1059-1069. http://doi.org/10.1093/ecco-jcc/jjac009 (2022). et al. Effectiveness of Switching From Intravenous to Subcutaneous Infliximab in Patients With Inflammatory Bowel Diseases: the REMSWITCH Study. Clin Gastroenterol Hepatol 21, 2338-2346.e2333. http://doi.org/10.1016/j.cgh.2022.08.011 (2023). et al. Budget impact analysis of the subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in the Big-5 European (E5) countries. BMC Health Serv Res 22, 1319. http://doi.org/10.1186/s12913-022-08683-y (2022). et al. Subcutaneous Infliximab [CT-P13], a True Biologic 2.0. Real Clinical Practice Multicentre Study. Biomedicines 10. http://doi.org/10.3390/biomedicines10092130 (2022). et al. One-Year Clinical Outcomes of Subcutaneous Infliximab Maintenance Therapy Compared With Intravenous Infliximab Maintenance Therapy in Patients With Inflammatory Bowel Disease: A Prospective Cohort Study. Inflamm Bowel Dis 30, 517-528. http://doi.org/10.1093/ibd/izad094 (2024). et al. Long-term prognosis of ulcerative colitis and its temporal changes between 1986 and 2015 in a population-based cohort in the Songpa-Kangdong district of Seoul, Korea. Gut 69, 1432-1440. http://doi.org/10.1136/gutjnl-2019-319699 (2020). et al. A 30-year Trend Analysis in the Epidemiology of Inflammatory Bowel Disease in the Songpa-Kangdong District of Seoul, Korea in 1986-2015. J Crohns Colitis 13, 1410-1417. http://doi.org/10.1093/ecco-jcc/jjz081 (2019).Korean J Intern Med 37, 885-894. http://doi.org/10.3904/kjim.2022.138 (2022).